Quanta Therapeutics Presents Positive Phase 1 Data for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, in Patients with Advanced Solid Tumors
– QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and…
PIVOT-PO Phase 3 Data Show Tebipenem HBrs Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint…
Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET…
Quanta Therapeutics Announces First Clinical Data Presentation for QTX3034, an Oral G12D-Preferring Multi-KRAS Inhibitor, at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE)…
Boehringers HERNEXEOS approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib…
U.S. Oral Surgery Management Moves into 31st State
IRVING, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- U.S. Oral Surgery Management…
COLGATE DENTAL VEER ANTHEM LAUNCHED TO EMPOWER KIDS TO BE THEIR OWN HEROES OF ORAL HEALTH
Released close to Independence Day, the anthem is penned by lyricist Swanand…
Government of Uttar Pradesh honors Colgate for reaching 60 lakh students with Oral Health Education through Bright Smiles, Bright Futures Program
Colgate further commits to training Anganwadi workers in Ayodhya to expand impact MUMBAI,…
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for…
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY (Paltusotine) in Acromegaly at ENDO 2025
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show…
